Cnnabis Use Disorder Pipeline Drugs and Companies Insight Report (2023): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Cnnabis Use Disorder pipeline constitutes 5+ key companies continuously working towards developing 5+ Cnnabis Use Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Cnnabis Use Disorder Overview
Cnnabis (also called marijuana) is the third most commonly used psychoactive substance worldwide, after alcohol and tobacco (nicotine). Cnnabis can be used by smoking, vaping, dabbing, ingesting (edibles, beverages, and tinctures), and topical cream. Cnnabis use disorder develops in approximately 10 percent of regular Cnnabis users and up to 50 percent of chronic daily users and may be associated with cognitive impairment, poor school or work performance, and psychiatric comorbidity such as mood disorders and psychosis.
"Cnnabis Use Disorder Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cnnabis Use Disorder Market.

The Cnnabis Use Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cnnabis Use Disorder Pipeline Report: https://www.delveinsight.com/report-store/Cnnabis-use-disorder-cud-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Cnnabis Use Disorder treatment therapies with a considerable amount of success over the years. Cnnabis Use Disorder Key players such as - Opiant Pharmaceuticals, NFL Biosciences, Anebulo Pharmaceuticals, Indivior, and others, are developing therapies for the Cnnabis Use Disorder treatment
• Cnnabis Use Disorder Emerging therapies such as - OPNT004, NFL-201, ANEB-001, AEF0117, and others are expected to have a significant impact on the Cnnabis Use Disorder market in the coming years.
• In June 2021, Indivior PLC, announced that it is extending its leadership position in substance use disorder ("SUD") treatment by expanding into the under treated Cnnabis-related disorders, including Cnnabis use disorder ("CUD") and Cnnabis-induced psychosis ("CIP")

Cnnabis Use Disorder Pipeline Therapeutics Assessment
• Cnnabis Use Disorder Assessment by Product Type
• Cnnabis Use Disorder By Stage and Product Type
• Cnnabis Use Disorder Assessment by Route of Administration
• Cnnabis Use Disorder By Stage and Route of Administration
• Cnnabis Use Disorder Assessment by Molecule Type
• Cnnabis Use Disorder by Stage and Molecule Type

DelveInsight's Cnnabis Use Disorder Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Cnnabis Use Disorder Drugs Under Different Phases of Clinical Development Include:
• OPNT004: Opiant Pharmaceuticals
• NFL-201: NFL Biosciences
• ANEB-001: Anebulo Pharmaceuticals
• AEF0117: Indivior

Get a Free Sample PDF Report to know more about Cnnabis Use Disorder Pipeline Assessment- https://www.delveinsight.com/sample-request/Cnnabis-use-disorder-cud-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cnnabis Use Disorder Pipeline Analysis:
The Cnnabis Use Disorder pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Cnnabis Use Disorder treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cnnabis Use Disorder Treatment.
• Cnnabis Use Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cnnabis Use Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cnnabis Use Disorder market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Cnnabis Use Disorder product details are provided in the report. Download the Cnnabis Use Disorder pipeline report to learn more about the emerging Cnnabis Use Disorder therapies at:
https://www.delveinsight.com/sample-request/Cnnabis-use-disorder-cud-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cnnabis Use Disorder Pipeline Market Drivers
• With more states and countries opening up to legal Cnnabis, there are growing concerns about a rise in addiction

Cnnabis Use Disorder Pipeline Market Barriers
• Much remains to be learned in order to advance public health and to guide personal and societal decisions regarding the use of Cnnabis
• Cnnabis is the most common substance of abuse besides alcohol and tobacco, and there is no FDA approved drug

Scope of Cnnabis Use Disorder Pipeline Drug Insight
• Coverage: Global
• Key Cnnabis Use Disorder Companies: Opiant Pharmaceuticals, NFL Biosciences, Anebulo Pharmaceuticals, Indivior, and others
• Key Cnnabis Use Disorder Therapies: OPNT004, NFL-201, ANEB-001, AEF0117, and others
• Cnnabis Use Disorder Therapeutic Assessment: Cnnabis Use Disorder current marketed and Cnnabis Use Disorder emerging therapies
• Cnnabis Use Disorder Market Dynamics: Cnnabis Use Disorder market drivers and Cnnabis Use Disorder market barriers

Request for Sample PDF Report for Cnnabis Use Disorder Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/Cnnabis-use-disorder-cud-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Cnnabis Use Disorder Report Introduction
2 Cnnabis Use Disorder Executive Summary
3 Cnnabis Use Disorder Overview
4 Cnnabis Use Disorder- Analytical Perspective In-depth Commercial Assessment
5 Cnnabis Use Disorder Pipeline Therapeutics
6 Cnnabis Use Disorder Late Stage Products (Phase II/III)
7 Cnnabis Use Disorder Mid Stage Products (Phase II)
8 Cnnabis Use Disorder Early Stage Products (Phase I)
9 Cnnabis Use Disorder Preclinical Stage Products
10 Cnnabis Use Disorder Therapeutics Assessment
11 Cnnabis Use Disorder Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Cnnabis Use Disorder Key Companies
14 Cnnabis Use Disorder Key Products
15 Cnnabis Use Disorder Unmet Needs
16 Cnnabis Use Disorder Market Drivers and Barriers
17 Cnnabis Use Disorder Future Perspectives and Conclusion
18 Cnnabis Use Disorder Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Cnnabis Use Disorder drugs and therapies- https://www.delveinsight.com/sample-request/Cnnabis-use-disorder-cud-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Cnnabis Use Disorder Market https://www.delveinsight.com/report-store/Cnnabis-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Cnnabis Use Disorder-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Latest Reports:
Related Reports By DelveInsight -

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.